Determining Modes of Action for Biologically Based Risk Assessments

1999 ◽  
Vol 30 (1) ◽  
pp. 75-79 ◽  
Author(s):  
Paul M. Schlosser ◽  
Matthew S. Bogdanffy
Keyword(s):  
Risk Assessments ◽  
Modes Of Action ◽  
Determining Modes

Column: Risk Assessments

Polymer News ◽  
2004 ◽  
Vol 29 (7) ◽  
pp. 220-223
Author(s):  
Charles Carraher, Jr.
Keyword(s):  
Risk Assessments

Column: Risk Assessments

Polymer News ◽  
2004 ◽  
Vol 29 (2) ◽  
pp. 58-60
Author(s):  
Charles Carraher, Jr.
Keyword(s):  
Risk Assessments

Effects of Differences in Numeric Ability on the Perception of Adversity Risk to Others and Self

2013 ◽  
Vol 25 (2) ◽  
pp. 95-104 ◽  
Author(s):  
Coy Callison ◽  
Rhonda Gibson ◽  
Dolf Zillmann
Keyword(s):  
Risk Assessments ◽  
High Ability ◽  
News Report ◽  
Bodily Injury ◽  
Adolescent Groups ◽  
Study Participants

This study used an experimental news report about confrontational robberies by adolescent groups in Mexican resorts that presented statistics with or without personalized cases of victimization. Study participants estimated the risk of harm to victims and the extent of their suffering. They also indicated their own risk and concern for their own safety. The readers’ numeric ability was ascertained thereafter. A trisection of this ability showed that persons of high ability comparatively overestimated others’ risk but underestimated their own; this despite indicating greater concerns for their own safety. These results were not altered by consideration of the readers’ empathic, experiential, and rational traits. The incorporation of personalized cases of victimization in the news report did not appreciably influence risk assessments. The involvement of cases resulting in major bodily injury, however, increased estimates of the incidence of such robberies.

How well do juvenile risk assessments measure factors to target in treatment? Examining construct validity.

2017 ◽  
Vol 29 (6) ◽  
pp. 679-691 ◽  
Author(s):  
Jennifer L. Skeem ◽  
Patrick J. Kennealy ◽  
Joseph R. Tatar ◽  
Isaias R. Hernandez ◽  
Felicia A. Keith
Keyword(s):  
Construct Validity ◽  
Risk Assessments

Therapeutic options in male osteoporosis

2013 ◽  
Vol 22 (04) ◽  
pp. 271-276 ◽  
Author(s):  
P. Farahmand ◽  
J. D. Ringe
Keyword(s):  
Risk Factors ◽  
Vitamin D ◽  
Public Health Problem ◽  
Male Osteoporosis ◽  
Individual Risk ◽  
Modes Of Action ◽  
Increased Risk ◽  
Study Results ◽  
Long Term Treatment ◽  
Male Patients

SummaryOsteoporosis in men is increasingly recognized as an important public health problem but affected patients are still under-diagnosed and -treated. As in women the diagnostic and therapeutic strategy has to be adapted to the individual case. In the practical management it is very important to detect possible causes of secondary osteoporosis, to explain the possibilities of basic therapy counteracting individual risk factors and communicate that osteoporosis is a chronic disease and adherence to a long-term treatment is crucial. In established severe osteoporosis a careful analgesic therapy is important to avoid further bone loss related to immobility. In elderly men with increased risk of falling insufficient Vitamin D supply or impaired activation of Vitamin D due to renal insufficiency must be taken into consideration. Specific medications available today for the treatment of male osteoporosis comprise among antiresorptive drugs the bis phosphonates alendronate, risedronate and zoledronic acid. Denosumab, the first biological therapy is approved for men with androgen deprivation therapy for prostate cancer. An important advantage of this potent antiresorptive drug is the increased adherence due to the comfortable application by sixmonthly subcutaneous injections. Study results from the 2-year multi-center randomized controlled ADAMO-Study will very soon allow the use of denosumab in all types of male osteoporosis. Teriparatide, the 34 N-terminal amino acid sequence of parathyroid hormone was approved for men with osteoporosis as an anabolic agent based on proven efficacy by different studies. Among drugs with other modes of action the D-hormone pro-drug alfacalcidol can be used in men alone or in combination with the advantage of pleiotropic effects on calcium absorption, parathyroids, bone and muscle. Recently also Strontium-ranelate was approved for male patients with the limitation to exclude men with clinical relevant cardiovascular risk factors. In general the possibilities to treat male osteoporosis have considerably improved during recent years. Today there is a choice of a spectrum of drugs from mild to strong potency with different modes of action on bone turnover to design strategies for individual male patients.

Sign in / Sign up

Export Citation Format

Share Document